Autoradiography studies demonstrated high correlation between the PET tracer 64Cu-cetuximab-F(ab’)2 and EGFR expression, showing the tracer’s potential to monitor tumour response to EGFR-inhibitor treatment. The gene discussed is EGFR; the disease is neoplasm.